Thursday, Gilead Sciences, Inc. (GILD) announced that the FDA has approved the supplemental new drug application or sNDA to expand the indication for Vemlidy also known as tenofovir alafenamide 25 mg tablets.
This approval allows for the once-daily treatment of chronic hepatitis B virus or HBV infection in pediatric patients aged six years and older, weighing at least 25 kg, with compensated liver disease.
In 2022, Vemlidy received FDA approval for pediatric patients aged 12 and older with compensated liver disease. Previously, in 2016, it was approved as a once-daily treatment for chronic HBV infection in adults.
The approval of Vemlidy for this pediatric patient population is backed by Week 96 data from a Phase 2 clinical trial that compared treatment with Vemlidy 25 mg to placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.